2022-11-04T11:46:56-05:00 2021-12-31 582676261 Rogers & Company PLLC 8300 Boone Boulevard Suite 600 Vienna VA 22182 990 2021-01-01 061389829 Albert B Sabin Vaccine Institute Inc ALBE 2028428610 2175 K Street NW 400 Washington DC 20037 Amy Finan Chief Executive Officer 2028428610 2022-11-04 1 Amy Finan 999009999 Jie Chen CPA P01049760 7038930300 3 AAL1 IAL1 2021 2022-09-23 18:48:47Z Amy Finan 2175 K Street NW 400 Washington DC 20037 26917386 0 X www.sabin.org X 1994 MD To make vaccines more accessible, enable innovation and expand immunization. 13 13 72 0 0 0 23177961 26883038 0 0 22343 30118 0 0 23200304 26913156 7944609 2232992 0 0 6514130 7670433 0 0 370014 6363719 16281894 20822458 26185319 2377846 727837 15923054 18738050 4483142 6518849 11439912 12219201 X To make vaccines more accessible, enable innovation and expand immunization across the globe. 0 0 14157133 Vaccine Research and Development:The Sabin Vaccine Institute supports innovative technologies and approaches in vaccine research and development to combat infectious and emerging threats to global health. Sabin's Research & Development strategy is to advance the development of vaccine candidates that have demonstrated early scientific value but have little commercial value, targeting diseases that impact the world's most vulnerable populations. Sabin leverages the expertise of partners in the academic, public, and private sectors, and promotes open-source research.Ebola has taken the lives of more than 15,000 people in the last many years. To protect communities across the globe from the critical threat posed by Ebola and the closely related, but lesser known, Marburg virus, Sabin is currently developing vaccines for Ebola Sudan and Marburg virus disease based on technology licensed from GSK. The prophylactic vaccine candidates are based on GSK's proprietary ChAd3 platform. In 2019, the U.S. Health and Human Services' Biomedical Advanced Research and Development Authority awarded Sabin a multi-year development contract to advance development of the Marburg and Ebola Sudan vaccines. 8796004 2232992 Global Immunization:Despite scientific advances and international support, 1.5 million people still die each year from diseases that could have been prevented by immunization. Sabin has a vision of a future free from such preventable diseases. Reaching this goal requires efficient vaccine distribution, broad vaccine uptake and equitable access to vaccination services. Through advocacy, capacity development and social, behavioral, and epidemiological research, Sabin advances evidence-based strategies for improved distribution and uptake of vaccines.Sabin's capacity-development activities help immunization professionals stay up to date on new vaccines, changing policies and recommendations, and developments in vaccine science; it also helps policy makers and the public to discern truth from fiction regarding vaccines and vaccination. Sabin's Boost global community enables immunization professionals to connect with peers and experts, learn skills that build capacity and advance careers, and lead immunization programs in challenging contexts. Sabin's Vaccine Acceptance & Demand workstream helps to dispel misinformation, understand the social drivers of vaccination decisions, and improve social and traditional media effects on vaccine confidence. Sabin drives vaccine innovation by bringing together big thinkers from various industries to accelerate development of a universal influenza vaccine. Through webinars, conferences and workshops Sabin brings together researchers, government officials, immunization specialists and journalists to support the introduction and expansion of new and under-utilized vaccines. Sabin also improves disease outcomes by generating essential epidemiological data for well-designed and efficiently implemented immunization programs and creating cost-effective diagnostics for diseases such as typhoid. 22953137 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 1 1 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 31 0 1 72 1 0 0 0 0 0 0 0 0 0 0 0 0 X 13 13 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MD DC NY CA FL WA X The Organization 2406059555 2175 K Street NW 400 Washington DC 20037 Adegbola Richard Trustee 2.00 X 0 0 0 Baylor Norman Trustee 2.00 X 0 0 0 Commins Holman Wendy Trustee 2.00 X 0 0 0 Djibo Yacine Trustee 2.00 X 0 0 0 Fox Elizabeth Trustee 2.00 X 0 0 0 Hoos Axel Trustee 2.00 X 0 0 0 Libson Jeffrey Trustee, Secretary 2.00 X X 0 0 0 Omer Saad Trustee 2.00 X 0 0 0 Rabinovich Regina Trustee, Chair 2.00 X X 0 0 0 Salisbury David Trustee 2.00 X 0 0 0 Shea Jacqueline Trustee 2.00 X 0 0 0 Suzich JoAnn Trustee 2.00 X 0 0 0 Thoren Peter Trustee, Vice Chair, Treasurer 2.00 X X 0 0 0 Finan Amy CEO 40.00 X 410472 0 24511 Davis Brian Chief Financial & Operating Officer 40.00 X 336422 0 39088 Gellin Bruce President, Global Immunization 40.00 X 179042 0 11738 Rustomjee Roxana Senior VP, Research & Development 40.00 X 306518 0 46054 Garrett Denise VP, Applied Epidemiology Programs 40.00 X 244445 0 28965 Hayward Tara VP, Resource Development & Policy 40.00 X 219034 0 26648 Woodin Mary Beth VP, Communications 40.00 X 211891 0 32345 Siler Jennifer VP, Global Community Engagement 40.00 X 215846 0 22085 2123670 0 231434 23 0 1 0 Reithera SRL Via di Castel Romano 100 Rome IT 00128 Bulk drug substance production for Ebola 5436500 Texas Biomedical Research Institute PO Box 760549 San Antonio TX 782450549 Immunogenicity and efficacy testing for 1717860 Batelle Memorial Institute Dept L 998 Columbus OH 43260 Clinical trial tests for R&D program 1677835 BDO USA LLP One International Place 4th Floor Boston MA 02110 Financial and Quality Management for R&D 1372812 ICON Government and Public Health Soluti 1265 Ridge Road Hinckley OH 44233 Clinical trial oversight for R&D program 870748 16 16841076 10041962 26883038 29272 29272 5076 4230 846 846 846 26913156 0 0 30118 X 660063 660063 1572929 1572929 1001275 820817 132186 48272 5522554 4680960 570445 271149 236558 112994 114742 8822 487460 232840 236441 18179 422586 231477 171919 19190 16485 14625 1860 3968 3968 13637718 13170574 467042 102 695004 575010 119994 120246 39963 79340 943 59884 26434 32427 1023 518274 518274 48983 33651 15227 105 286925 271215 15710 367058 252600 114458 122862 75730 47132 Recruitment 257031 86649 170382 Dues/subscriptions 113674 86691 24786 2197 Miscellaneous 33688 7873 25783 32 Books & publications 94 42 52 26185319 22953137 2862168 370014 2245300 2243106 5989051 8663012 4494130 4847484 40848 4154 210032 310497 1545596 844800 791604 700796 444936 514448 1707153 1454553 15923054 18738050 2635445 4708737 1847697 1810112 4483142 6518849 X 1815408 2745224 9624504 9473977 11439912 12219201 15923054 18738050 727837 51452 0 X X 0 1 X 1 1 1 X 8075830 10410527 9462400 23177961 26883038 78009756 8075830 10410527 9462400 23177961 26883038 78009756 35133056 42876700 27008 98272 147130 22343 29272 324025 15222 17077 32299 78366080 1225 0.54710 0.50320 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 108 108 26185211 26185319 1000000 250000 0 0 669505 838024 1000000 1000000 3507529 5261294 59 108 167 167376 209506 250000 250000 876882 1315323 1192938 515133 677805 352658 329667 22991 700796 Deferred rent 1254228 Deferred compensation liability 555884 1810112 X 27016906 51452 52298 103750 26913156 0 26913156 26237617 52298 52298 26185319 0 26185319 Part X, Line 2: Management evaluated the Institute's tax positions and concluded that the Institute's financial statements do not include any uncertain tax positions. 1 South Asia 0 0 Grants to recipients located in region Typhoid study sites, Vaccine Acceptance Small Grants Program awardee 1429504 Sub-Saharan Africa - Angola, Benin, Botswana, Burkina Faso, 0 0 Grants to recipients located in region Vaccine Acceptance Small Grants Program awardee 82508 Europe (Including Iceland & Greenland) - Albania, Andorra, Austria,Belgium 0 0 Grants to recipients located in region Bulk drug substance production for ebola/marburg, Vaccine Acceptance Small Grants Program awardee 11000 Central America and the Caribbean 0 0 Grants to recipients located in region Vaccine Acceptance Small Grants Program awardee 4916 East Asia and the Pacific 0 0 Grants to recipients located in region Vaccine Acceptance Small Grants Program awardee 45000 0 0 0 0 0 0 1572928 0 1572928 South Asia - Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Typhoid study site 709239 EFT 0 South Asia - Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Vaccine Acceptance Small Grants Program awardee 40500 EFT 0 South Asia - Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Vaccine Acceptance Small Grants Program awardee 44948 EFT 0 Sub-Saharan Africa - Angola, Benin, Botswana, Burkina Faso, Vaccine Acceptance Small Grants Program awardee 31518 EFT 0 South Asia - Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Typhoid study site 203415 EFT 0 South Asia - Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Typhoid study site 419282 EFT 0 East Asia and the Pacific Vaccine Acceptance Small Grants Program awardee 45000 EFT 0 Sub-Saharan Africa - Angola, Benin, Botswana, Burkina Faso, Vaccine Acceptance Small Grants Program awardee 45000 EFT 0 14 0 Vaccine Acceptance Small Grants Program awardee Europe (Including Iceland & Greenland) - Albania, Andorra, Austria, Belgiu 1 11000 EFT Vaccine Acceptance Small Grants Program awardee Vaccine Acceptance Small Grants Program awardee Sub-Saharan Africa 1 2996 EFT 0 0 0 0 0 0 Part I, Line 2: Grants are monitored in several ways. First, there is a due diligence process in awarding the grant. Second, a written and signed agreement is executed, which includes a detailed scope of work, budget and reporting requirements. Typically, payments are sent either when milestones are met or in accordance with an established payment schedule. Third, we require monthly, quarterly, and/or annual financial and technical reports from recipients prior to sending the subsequent payment. Fourth, and as needed, we conduct site visits. And finally, if deemed necessary, a third party reviews the accounting records of the recipient(s). Part III Accounting Method: 1 AIDS Vaccine Advocacy Coalition 423 West 127th Street 4th Floor New York NY 10027 943240841 501c3 24725 0 Vaccine Acceptance Small Grants Program awardee International Women's Media Foundation 1625 K Street NW Suite 1275 Washington DC 20006 521648942 501c3 112500 0 Vaccine Acceptance Small Grants Program awardee Johns Hopkins University 12529 Collections Center Drive Chicago IL 60693 520595110 501c3 209074 0 Social media research Vaccine Acceptance Massachusetts General Hospital 55 Fruit Street GRJ 504 Boston MA 02114 041564655 501c3 90406 0 Typhoid study site Stanford University Lockbox PO Box 44253 San Francisco CA 94144 941156365 501c3 213658 0 Typhoid study site 5 0 Part I, Line 2: Grants are monitored in several ways. First, there is a due diligence process in awarding the grant. Second, a written and signed agreement is executed, which includes a detailed scope of work, budget and reporting requirements. Typically, payments are sent either when milestones are met or in accordance with an established payment schedule. Third, we require monthly, quarterly, and/or annual financial and technical reports from recipients prior to sending the subsequent payment. Fourth, and as needed, we conduct site visits. And finally, if deemed necessary, a third party reviews the accounting records of the recipient(s). X X X X X X 0 0 0 0 0 0 0 0 0 Finan Amy CEO 374472 0 36000 0 0 0 10128 0 14383 0 434983 0 0 0 Davis Brian Chief Financial & Operating Officer 303922 0 32500 0 0 0 10284 0 28804 0 375510 0 0 0 Rustomjee Roxana Senior VP, Research & Development 293718 0 12800 0 0 0 11064 0 34990 0 352572 0 0 0 Garrett Denise VP, Applied Epidemiology Programs 239445 0 5000 0 0 0 9636 0 19329 0 273410 0 0 0 Hayward Tara VP, Resource Development & Policy 207534 0 11500 0 0 0 8114 0 18534 0 245682 0 0 0 Woodin Mary Beth VP, Communications 206891 0 5000 0 0 0 8036 0 24309 0 244236 0 0 0 Siler Jennifer VP, Global Community Engagement 208846 0 7000 0 0 0 4257 0 17828 0 237931 0 0 0 Gellin Bruce President, Global Immunization 179042 0 0 0 0 0 6480 0 5258 0 190780 0 0 0 Form 990, Part VI, Section B, line 11b The Form 990 is prepared by an outside tax accounting firm based on independently audited financial statements. The Form 990 is then reviewed by the Director, Accounting and COO. Then the Form 990 is presented to the CEO and Finance and Audit Committee for their review and approval. Finally it is presented to the full Board of Trustees for their review before filing. Form 990, Part VI, Section B, line 12c Sabin's management, Board Chair and Governance Committee are reponsible for ensuring the conflict of interest policy is up-to-date and adhered to by the Trustees. Form 990, Part VI, Section B, line 15 Compensation of officers and/or key employees is set in consultation with input from the Board, Executive Committe or Chair as appropriate. Sabin uses a mix of data points including: independent salary surveys; comparable pay by similar organizations; compensation firms and our own internal pay scale. Form 990, Part VI, Section C, line 19 Governing documents (upon request), conflict of interest policy (upon request), and financial statement and Form 990 (Sabin's website). Form 990, Part IX, line 11g Transcription/translation service: Program service expenses 22,127. Management and general expenses 64. Fundraising expenses 0. Total expenses 22,191. Consultants: Program service expenses 3,169,420. Management and general expenses 466,708. Fundraising expenses 0. Total expenses 3,636,128. Contractor: Program service expenses 9,979,027. Management and general expenses 0. Fundraising expenses 0. Total expenses 9,979,027. Temporary staff: Program service expenses 0. Management and general expenses 270. Fundraising expenses 102. Total expenses 372. Form 990, Part XII, Line 2c: The Organization has a Finance and Audit Committee that assumes responsibility for oversight of the audit. This process is consistent with prior years.